TY - JOUR
T1 - A clinical study on the beneficial effects of nilvadipine on left ventricular hypertrophy in patients with hypertension
AU - Momomura, S.
AU - Takabatake, Y.
AU - Hayashi, T.
AU - Yoshimoto, N.
AU - Tanaka, S.
AU - Murayama, M.
AU - Tanabe, K.
AU - Sugishita, Y.
AU - Inoue, K.
AU - Yamamoto, M.
AU - Sawada, J.
AU - Ohkawa, S.
AU - Eguchi, M.
AU - Maeda, S.
AU - Nakajima, K.
AU - Nonaka, Y.
AU - Tamiya, E.
AU - Kinugawa, K.
PY - 1994
Y1 - 1994
N2 - To investigate the effect of nilvadipine on regression of left ventricular hypertrophy (LVH) in patients with hypertension, studies have been conducted through a cooperative effort by various medical centers. 48 patients with hypertensive left ventricular hypertrophy were subjects in these studies. The patients were given 8 mg/day of nilvadipine orally for 6 consecutive months. In 33 of the 48 patients, a variety of parameters including ECG, echocardiography, etc were analyzed. Systolic (from 171 ± 15 mmHg to 140 ± 15 mmHg, p < 0.01) and diastolic blood pressure (from 104 ± 10 mmHg to 87 ± 12 mmHg, p < 0.01) were both decreased by this treatment, while heart rate remained unchanged (70 ± 12 to 69 ± 8 beats/min). Cardio-thoracic ratio decreased slightly (from 53.6 ± 4.7 to 52.2 ± 4.8%, 6 < 0.01). As indices of LVH, RV5 + SV1 in ECG decreased from 38.8 ± 11.1 mm to 35.5 ± 10.8 mm (p < 0.05). In echocardiogram, it was shown that posterior wall thickness decreased significantly from 12.3 ± 1.7 mm to 11.0 ± 1.7 mm (p < 0.001), although the thickness of the interventricular septum was unchanged (from 12.5 ± 2.2 mm to 12.0 ± 2.3 mm). Calculated left ventricular mass also decreased significantly from 280 ± 76 g to 257 ± 80 g (p < 0.05). Thus, it was concluded that nilvadipine has a favourable effect on the regression of LVH, as well as having an antihypertensive effect. We concluded that this new calcium antagonist is beneficial for patients with hypertensive LVH.
AB - To investigate the effect of nilvadipine on regression of left ventricular hypertrophy (LVH) in patients with hypertension, studies have been conducted through a cooperative effort by various medical centers. 48 patients with hypertensive left ventricular hypertrophy were subjects in these studies. The patients were given 8 mg/day of nilvadipine orally for 6 consecutive months. In 33 of the 48 patients, a variety of parameters including ECG, echocardiography, etc were analyzed. Systolic (from 171 ± 15 mmHg to 140 ± 15 mmHg, p < 0.01) and diastolic blood pressure (from 104 ± 10 mmHg to 87 ± 12 mmHg, p < 0.01) were both decreased by this treatment, while heart rate remained unchanged (70 ± 12 to 69 ± 8 beats/min). Cardio-thoracic ratio decreased slightly (from 53.6 ± 4.7 to 52.2 ± 4.8%, 6 < 0.01). As indices of LVH, RV5 + SV1 in ECG decreased from 38.8 ± 11.1 mm to 35.5 ± 10.8 mm (p < 0.05). In echocardiogram, it was shown that posterior wall thickness decreased significantly from 12.3 ± 1.7 mm to 11.0 ± 1.7 mm (p < 0.001), although the thickness of the interventricular septum was unchanged (from 12.5 ± 2.2 mm to 12.0 ± 2.3 mm). Calculated left ventricular mass also decreased significantly from 280 ± 76 g to 257 ± 80 g (p < 0.05). Thus, it was concluded that nilvadipine has a favourable effect on the regression of LVH, as well as having an antihypertensive effect. We concluded that this new calcium antagonist is beneficial for patients with hypertensive LVH.
KW - hypertension
KW - left ventricular hypertrophy
KW - nilvadipine
UR - http://www.scopus.com/inward/record.url?scp=0027972339&partnerID=8YFLogxK
M3 - 学術論文
AN - SCOPUS:0027972339
SN - 0452-3458
VL - 42
SP - 153
EP - 159
JO - Respiration and Circulation
JF - Respiration and Circulation
IS - 2
ER -